Brittany Boswell1,2, Susan A Rudders3,4, Julie C Brown5,6. 1. Seattle Children's Hospital, Seattle, WA, USA. brittany.boswell@seattlechildrens.org. 2. Division of Emergency Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA. brittany.boswell@seattlechildrens.org. 3. Boston Children's Hospital, Boston, MA, USA. 4. Division of Immunology, Department of Pediatrics, Harvard Medical School, Boston, MA, USA. 5. Seattle Children's Hospital, Seattle, WA, USA. 6. Division of Emergency Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA.
Abstract
PURPOSE OF REVIEW: Anaphylaxis is a severe, life-threatening, systemic allergic reaction that should be recognized and treated promptly. Intramuscular (IM) epinephrine is the first-line treatment for anaphylaxis and there are no absolute contraindications to its use. Despite its established track record of efficacy and safety, physicians and patients face barriers in the recognition and treatment of anaphylaxis, including the maintenance and appropriate use of epinephrine auto-injectors. This has led to investigation into potential alternatives to IM epinephrine administration in anaphylaxis. RECENT FINDINGS: This review investigates the current standard of care in the treatment of anaphylaxis, barriers to IM epinephrine use, and alternative therapies under investigation for administration in anaphylaxis. Alternative routes under investigation include intranasal, sublingual, inhaled, and needle-free intramuscular administration of epinephrine. There are currently numerous investigational alternatives to IM epinephrine therapy which could hold promise as future effective treatments in the emergent management of anaphylaxis.
PURPOSE OF REVIEW: Anaphylaxis is a severe, life-threatening, systemic allergic reaction that should be recognized and treated promptly. Intramuscular (IM) epinephrine is the first-line treatment for anaphylaxis and there are no absolute contraindications to its use. Despite its established track record of efficacy and safety, physicians and patients face barriers in the recognition and treatment of anaphylaxis, including the maintenance and appropriate use of epinephrine auto-injectors. This has led to investigation into potential alternatives to IM epinephrine administration in anaphylaxis. RECENT FINDINGS: This review investigates the current standard of care in the treatment of anaphylaxis, barriers to IM epinephrine use, and alternative therapies under investigation for administration in anaphylaxis. Alternative routes under investigation include intranasal, sublingual, inhaled, and needle-free intramuscular administration of epinephrine. There are currently numerous investigational alternatives to IM epinephrine therapy which could hold promise as future effective treatments in the emergent management of anaphylaxis.
Entities:
Keywords:
Allergy; Anaphylaxis; Epinephrine; Epinephrine auto injector; Intramuscular alternative
Authors: Phillip Lieberman; Richard A Nicklas; Christopher Randolph; John Oppenheimer; David Bernstein; Jonathan Bernstein; Anne Ellis; David B K Golden; Paul Greenberger; Steven Kemp; David Khan; Dennis Ledford; Jay Lieberman; Dean Metcalfe; Anna Nowak-Wegrzyn; Scott Sicherer; Dana Wallace; Joann Blessing-Moore; David Lang; Jay M Portnoy; Diane Schuller; Sheldon Spector; Stephen A Tilles Journal: Ann Allergy Asthma Immunol Date: 2015-11 Impact factor: 6.347
Authors: Phillip Lieberman; Richard A Nicklas; John Oppenheimer; Stephen F Kemp; David M Lang; David I Bernstein; Jonathan A Bernstein; A Wesley Burks; Anna M Feldweg; Jordan N Fink; Paul A Greenberger; David B K Golden; John M James; Stephen F Kemp; Dennis K Ledford; Phillip Lieberman; Albert L Sheffer; David I Bernstein; Joann Blessing-Moore; Linda Cox; David A Khan; David Lang; Richard A Nicklas; John Oppenheimer; Jay M Portnoy; Christopher Randolph; Diane E Schuller; Sheldon L Spector; Stephen Tilles; Dana Wallace Journal: J Allergy Clin Immunol Date: 2010-08-07 Impact factor: 10.793
Authors: S Dhami; S S Panesar; G Roberts; A Muraro; M Worm; M B Bilò; V Cardona; A E J Dubois; A DunnGalvin; P Eigenmann; M Fernandez-Rivas; S Halken; G Lack; B Niggemann; F Rueff; A F Santos; B Vlieg-Boerstra; Z Q Zolkipli; A Sheikh Journal: Allergy Date: 2013-11-20 Impact factor: 13.146
Authors: F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Yehia M El-Gamal; Dennis K Ledford; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong Journal: World Allergy Organ J Date: 2011-02-23 Impact factor: 4.084